Purpose: Differentiating tumor from its surrounding soft tissues is challenging for x-ray computed tomography (CT). Fluorescence molecular tomography (FMT) can directly localize the internal tumors targeted with specific fluorescent probes. A FMT system was developed and integrated onto a CT-guided irradiator to improve tumor localization for image-guided radiation. Methods: The FMT system was aligned orthogonal to the cone-beam CT onboard our previously developed image-guided small animal arc radiation treatment system (iSMAART). Through rigorous physical registration, the onboard CT provides accurate surface contour which is used to generate three-dimensional mesh for FMT reconstruction. During FMT experiments, a point laser source perpendicular to the rotating axis was used to excite the internal fluorophores. The normalized optical images from multiple projection angles were adopted for tomographic reconstruction. To investigate the accuracy of the FMT in locating the tumor and recovering its volume, in vivo experiments were conducted on two breast cancer models: MDA-MB-231 cancer xenograft on nude mice and 4T1 cancer xenograft on white mice. Both cancer cell lines overexpress the epidermal growth factor receptor (EGFR). A novel fluorescent poly(lactic-co-glycolic) acid (PLGA) nanoparticle conjugated with anti-EGFR was intravenously injected to specifically target the breast cancer cells. Another ex vivo experiment on a mouse bearing a surgically implanted Indocyanine Green-containing glass tube was conducted, to additionally validate the precision of FMT-guided radiation therapy. Results: The FMT can accurately localize the single-nodule breast tumors actively targeted with fluorescent nanoparticles with localization error < 0.5 mm calculated between the centers of mass of tumors in FMT and CT. The reconstructed tumor volume in FMT was significantly correlated with that in the iodinated contrast-enhanced CT (R 2 = 0.94, P < 0.001). The FMT was able to guide focal radiation delivery with submillimeter accuracy. Conclusion: Using the tumor-targeting fluorescent probes, the iSMAART with onboard FMT system can accurately differentiate tumors from their surrounding soft tissue, guide precise focal radiation delivery, and potentially assess tumor response in cancer research.
INTRODUCTION
Radiotherapy studies on various small animal cancer models mimicking human treatment are useful to test potential therapeutics. 1 Several small animal irradiators based on x-ray computed tomography (CT) guidance have been developed, including our recently developed image-guided SMall Animal Arc Radiation Treatment system (iSMAART). [2] [3] [4] [5] The performance of the iSMAART system has been thoroughly evaluated, including CT imaging quality, image guidance capability, animal positioning stability, radiation targeting precision, and stereotactic radiation beam delivery. 5 Although CT provides excellent bone to soft tissue contrast and is indispensable for tumor irradiation guidance, differentiating tumor from its surrounding soft tissues remains challenging. Iodinated contrast CT may be able to differentiate some tumor types, but it fails for poorly vascularized tumor types. [6] [7] [8] To overcome this challenge, preclinical irradiation systems can integrate with different functional imaging modalities that have superior tumor to soft tissue contrast, such as magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), positron emission tomography (PET), and optical molecular imaging. [9] [10] [11] [12] Two common modalities for optical molecular imaging, bioluminescence and fluorescence imaging, are particularly attractive, considering their affordability, simplicity, high throughput and both are free of ionizing-radiation. 13 Integration of bioluminescence tomography (BLT) system onto the iSMAART platform is reported in the part 1 of this series. The current study focuses on the integration of fluorescence molecular tomography (FMT) system onto the iSMAART platform.
By exploiting the specificity of fluorescent biomarkers, fluorescence molecular imaging can be used to monitor tumor growth and evaluate treatment responses, and has broad applications in biomedical research.
14 Fluorescence imaging, however, faces a challenge when it comes to threedimensional reconstruction of the fluorophore-marked tumor volume. In contrast to x-ray imaging, photon scattering dominates the lower energy visible light photon propagation through tissue. Therefore, the inverse problem for FMT reconstruction is inherently ill-posed and susceptible to noise and model errors. 15 Many high-performance reconstruction algorithms have been proposed to overcome these problems. [16] [17] [18] Combining the specific fluorescence probes and high-performance reconstruction algorithms, FMT has the potential of guiding focal irradiation to the tumor targets, while sparing the surrounding healthy tissues. To our best knowledge, this is the first time demonstration of an integrated CT, FMT, and stereotactic irradiation system.
In this study, a novel poly(lactic-co-glycolic) acid (PLGA) nanoparticle conjugated with both near-infrared fluorophores and antiepidermal growth factor receptors (anti-EGFR) was constructed to actively target breast cancer cells. To demonstrate the capability of the FMT onboard the iSMAART platform, in vivo experiments were conducted on two breast tumor models, the MDA-MB-231 cell line with nude mice and the 4T1 cell line with white mice. The iodinated contrast CT onboard the iSMAART was used to delineate the breast tumor, providing a solid benchmark against the FMT performance. In vivo mice experiments demonstrate that FMT can accurately localize the breast tumor with < 0.5 mm error. Linear regression shows significant correlation between the tumor volume reconstructed from FMT and contrast CT. In addition, another ex vivo experiment performed on a mouse bearing surgically implanted Indocyanine Green (ICG)-containing glass tube further validated that the FMT onboard iSMAART can precisely guide focal irradiation with submillimeter accuracy.
This paper is organized as follows: Section 2 presents the configuration of the iSMAART with the onboard FMT, the fluorescent PLGA-anti-EGFR nanoparticle, the method for FMT reconstruction and FMT-guided radiation. In vivo mice experiments and results are shown in Section 3 to demonstrate the capabilities of the onboard FMT system in tumor reconstruction and radiation guidance. Finally, Section 4 discusses and concludes the studies. Figure 1 shows the schematic diagram of the integrated iSMAART platform after the FMT integration. The FMT system is similar to the BLT system in part 1, except that a fiber-coupled laser is added to provide the exciting light for fluorescence imaging. Laser light from a 4-channel (645 nm, 785 nm, 856 nm, and 972 nm) fiber-coupled laser source (Thorlabs, Newton, NJ, USA) was used for fluorescence excitation. The light was transmitted through a multimode fiber and was collimated through fiber collimation before irradiating the mouse surface. The distance from the axis of rotating stage to the fiber collimation and the mirror is 6 cm and 35 cm, respectively. Band-pass filters with different center wavelengths (650 nm-850 nm, Semrock, Rochester, NY, USA) were mounted on a filter wheel in front of the CCD camera (Andor Technology, Belfast, Northern Ireland) coupled with a Nikon 50 mm f/1.8 lens, to collect the fluorescence light from different fluorophores. In this system, we define 90°as the direction where the CCD faces the anterior part of mice (ventral view). CT, BLT, and FMT all share the same coordinates.
MATERIALS AND METHODS

2.A. System configuration
2.B. Fluorescent PLGA-anti-EGFR nanoparticles
PLGA material has wide applications in nanomedicine, because it can be readily hydrolyzed in the human body to nontoxic and biodegradable lactic and glycolic acids. 19 In this study, a near-infrared fluorescence PLGA particles (excitation/emission: 780 nm/820 nm; Phosphorex, Inc, Hopkinton, MA, USA) were synthesized in the nonpolar core of an oilin-water microemulsion with PEGylated phospholipid DSPEmPEG 2000 as the emulsifier. In order to selectively target the EGFR-overexpressing breast tumor, the anti-EGFR antibodies (Thermo Fisher Scientific, Inc, Waltham, MA, USA) were conjugated to the PLGA particles using 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) chemistry according to a previously described procedure. 20 The control PLGA nanoparticles were conjugated with a nonselective antibody immunoglobulin G. Dynamic light scattering method was employed to measure the size, distribution, and zeta potential of the particles. The results showed that the size was 262.9 AE 80.5 nm and zeta potential À11.2 mV. Figure 2 is for the recognition of cell nucleus. The two cell groups were cultured with the same concentration of nanoparticles (250 lg/mL).
2.C. Pharmacokinetics of the PLGA-anti-EGFR nanoparticle
All animal experiments were conducted under protocols approved by the institutional animal care and use committee. The in vivo pharmacokinetics experiments were conducted on two cancer models: the female athymic nude mice inoculated with the MDA-MB-231 breast tumor (n = 4 for PLGA-anti-EGFR group, and n = 3 for PLGA-IgG group) and female BALB/c white mice inoculated with the 4T1 breast tumor (n = 4 for PLGA-anti-EGFR group, and n = 3 for PLGA-IgG group), to compare the in vivo targeting efficiency of the two different nanoparticles. To develop the breast cancer model, 5 9 10 5 cells were injected into the mammary fat pad of 4-week old mice. The pharmacokinetics study was performed 3 weeks after tumor cell inoculation. The nanoparticles (300 lL, 10 mg/ml) were administered via tail vein injection after the animal was anesthetized with 2% isoflurane.
2.D. FMT reconstruction
The propagation of near-infrared light in tissues is usually modeled by the coupled diffusion equations (DE) with Robintype boundary condition, particularly when light transport is dominated by scattering and the sources and detectors are separated by more than a few mean free paths. 15 In this study, the normalized Born approximation to DE is adopted to alleviate the sensitivity of FMT forward model to the theoretical errors about boundary conditions and tissue optical properties. 21 Based on the Born approximation, the Born normalization intensity / f (r d , r s ) at detector location r d corresponding to an excitation spot located at r s can be formulated as follows:
where / em (r d , r s ) and / ex (r d , r s ) denote the measured light intensity at the emission wavelength k em and excitation wavelength k ex , respectively. G(r s , r, k ex ) is the theoretically modeled light field at the excitation wavelength k ex induced at position r by a source at position r s . G(r d , r, k em ) is the Green's function describing photon propagation from point r to the detector point r d at the emission wavelength k em . D f is the diffusion coefficient of the tissue at wavelength k em . S 0 is a calibration factor accounting for various system gains and attenuation factors. υ is the photon speed in tissue. After discretizing the imaging domain generated from the 3D-CT surface, the FMT forward model can be analytically solved by the Kirchhoff approximation method. 22 Then, the FMT problem can be formulated as the following linear matrix equation:
where the sensitive matrix W maps the fluorophore distribution vector X onto the measured fluorescent signal vector Φ f . FMT reconstruction is to infer the internal fluorophore distribution by solving Eq. (2) through inverting matrix W. To guarantee the stability and uniqueness of the solution for the FMT inverse problem, sparsity promoting regularization is commonly employed. [16] [17] [18] The FMT reconstruction problem can be formulated as the following optimization function: arg min
where the diagonal regularization matrix Λ is iteratively updated to balance the data fitting WX À U f 2 2 and sparsity penalty function h(X).
2.E. Tomographic imaging experiments
To evaluate the capability of the FMT onboard iSMAART platform, in vivo imaging experiments were conducted on 4 nude mice with MDA-MB-231 tumors and 4 white mice with 4T1 tumors. Contrast CT was used to benchmark against the FMT performance. Thus, the FMT experiments were carried out after the tumor can be detected by contrast CT. Both 4T1 and MDA-MAB-231 breast tumors are well vascularized. About 3 weeks after cancer cell injection, tumors grew large enough (≥ 20 mm 3 ) and were delineated by contrast CT. In these tomographic experiments, mice were imaged at different time points during a range of 4-6 weeks after tumor inoculation, to validate the capability of quantifying different tumor sizes. The imaging was performed 1 day after the PLGA-anti-EGFR nanoparticles were injected through tail vein. Before FMT imaging, the white mice were shaved around the abdominal region to prevent the fur-induced light scattering artifact. All the animals were anesthetized by subcutaneous injection of a ketamine:xylazine cocktail (100:10 mg/kg body weight). Then, they were intravenously administered 200 lL iodinated contrast agent Iopamidol (1000 mg/kg body weight) for contrast CT to delineate the breast tumor. Details for the contrast CT imaging can be found in the part 1. For FMT, a laser light centered at 780 nm wavelength was employed to excite the internal near-infrared fluorescent PLGA-anti-EGFR nanoparticles. A bandpass filter centered at 810 nm wavelength was placed in front of the CCD to collect fluorescence signals at multiple angles (70°, 90°, 110°, 250°, 270°, 290°). To obtain the Born normalization following Formula (1), both excitation and emission signals are acquired. During acquisition of the excitation signal, a neutral filter (OD = 2) was used in place of the fluorescence filter to reduce the intensity of the excitation light reaching the CCD camera. The CCD is set with exposure time of 1 s and 4 9 4 binning for both excitation and emission light acquisition. The laser power was set to be 25 mW. The FMT acquisition took about 2 min. The CT and FMT acquisition together took about 3 min. After imaging, the mice were moved to a warm thermal chamber for recovery. All the mice survived after the imaging experiment. The absorption and reduced scattering coefficients used in the FMT reconstruction were set to 0.03 cm À1 and 10.7 cm À1 , respectively, referring to the optical properties in mice abdomen and assuming a homogeneous tissue volume. 23 
2.F. FMT-guided radiation
The FMT shares the same coordinates as the CBCT and stereotactic radiation on the iSMAART platform. Therefore, CBCT-assisted FMT can directly guide radiation dose delivery. The workflow of our online FMT-guided irradiation is as The concept of FMT-guided radiotherapy was validated through an ex vivo experiment by imaging and radiation targeting an ICG-containing glass tube (2.5 mm diameter and 14.5 mm height, 1.5 lM ICG concentration) surgically implanted in a euthanized nude mouse. The ICG concentration used is physiologically relevant and has been used to mimic the actual ICG concentration in the mouse blood. 24 Following FMT imaging, the COM of the ICG volume identified in the FMT reconstruction was aligned to the center of a 20 mm collimator. The glass tube is radiopaque and can be visualized in the x-ray projection image. One can tell the FMT targeting accuracy by measuring the offset between the collimator center and the true glass tube canter in the x-ray beam eye views.
RESULTS
3.A. Pharmacokinetics of the PLGA-anti-EGFR nanoparticle
A Kodak In Vivo Multispectral Imaging system (Carestream Health, New Haven, CT, USA) was used to monitor the whole body fluorescence signal at different time points within one week after the nanoparticle injection. Figures 3(a) and 3(f) plot the mean fluorescence signal intensity from a region of interest covering the tumor area, for the two tumor models. Consistent with the in vitro experiment results (Fig. 2) , the in vivo fluorescence signal was much stronger for the group with the PLGA-anti-EGFR nanoparticle, confirming its higher efficiency in targeting EGFR-overexpressing breast tumors. Figures 3(b)-3 (e) and 3(g)-3(i) demonstrate the longitudinal fluorescent images following the PLGA-anti-EGFR nanoparticle injection for different tumor models. Similar results were acquired for both models. The results indicate that the active targeting nanoparticles reach their peak accumulation in the tumor at~1 day after injection, and then gradually wash out from the tumor site. A significant amount of PLGA-anti-EGFR nanoparticles were retained in the tumor for more than 1 week, rendering a prolonged temporal window for fluorescence imaging of the breast tumor. Figures 3(k)-3(n) demonstrate that, without anti-EGFR targeting, there was much less amount of nanoparticles accumulated in the tumor site. Based on the pharmacokinetic results, the FMT experiments were conducted at 1 day after nanoparticle injection, to capture the peak tumor fluorescence enhancement. of one MDA-MB-231 tumor and one 4T1 tumor in three orthogonal views. The tumors were delineated by the peripheral contrast enhancement for both tumor models. Because the FMT and CBCT are physically registered with each other on the iSMAART, the tumor outlined in the contrast CT can be used as a benchmark against the FMT performance.
3.B. Tomographic imaging experiments
As an example, Fig. 5 shows the FMT results of 2 nude mice bearing MDA-MB-231 tumors and 2 white mice bearing 4T1 tumors. In this paper, an experiential 20% threshold was applied on the FMT reconstruction to assess the FMTbased tumor volume. The first row displays the 3D rendering of the CBCT bony anatomy fused with the FMT tumor, and remaining rows display three orthogonal views where the FMT slice is superimposed on the CBCT slice. The red lines denote the mouse contour used in the FMT reconstruction. The white dotted lines are the tumor contours obtained from the contrast CBCT. The color wash represents the fluorescence signal reconstructed in the FMT. It is observed that the tumors reconstructed in the FMT are coincident with their true locations identified from the contrast CBCT in all three orthogonal views. The average localization error between the FMT and CBCT tumor center of mass (COM) was 0.4 AE 0.1 mm (n = 8).
Our previous study has shown that the tumor volume calculated in the contrast CT is accurate to represent the true tumor volume, as long as the tumor is enhanced by the contrast and clearly delineated. 5 Therefore, to further validate the accuracy of the FMT in quantifying tumor volume, the tumor volumes calculated in the FMT were correlated to their corresponding CBCT volumes using the Pearson correlation analysis. The result indicates a significant correlation (R 2 = 0.94, P < 0.001) between these two tumor volumes (Fig. 6) .
3.C. FMT-guided radiation
The FMT reconstruction results are shown in Figs. 7(a)-7(d) . The 3D volume rendering in Fig. 7(a) The crosshair indicates the center of the 20 mm circular collimator guided by the FMT, and the little square marks the true center of the ICG volume detected from the CBCT. The average offset between the two centers was 0.3 AE 0.2 mm.
DISCUSSION AND CONCLUSION
A significant correlation was observed between the tumor volumes reconstructed in the FMT and contrast CT. The FMT-reconstructed tumor volume, however, was larger than the truth. This may result in the over-irradiation of healthy tissues surrounding the tumor target. Notwithstanding, the overirradiation accounts for only a small absolute volume, which is estimated to be a moderate margin expansion of less than 1 mm. For example, when the breast tumor volume is 223 mm 3 , the FMT-reconstructed volume is 305 mm 3 which is 37% overestimation. This overestimation is equivalent to a moderate tumor margin expansion of about 0.8 mm.
Although the COM of the fluorescent target reconstructed in the FMT agrees well with the truth, the volume reconstructed is larger than the truth and the exact boundary could not be accurately restored. As discussed in the part 1, it is very difficult, if not impossible, for the BLT or FMT to restore the exact boundary of any imaged object. The reconstruction accuracy may be compounded by the maximum depth of the tumor imaged and complex fluorescence intensity distribution. Similar to the BLT reconstruction, the FMT reconstruction also represents a well-known ill-conditioned inverse problem and still faces great challenges. 15 A few approaches can be used to improve the accuracy particularly in the reconstruction of irregularly shaped fluorescent targets. More sophisticated photon transport model, such as those based on high-order simplified spherical harmonics approximation or Monte Carlo, can be employed to more accurately model the internal light propagation. 25, 26 Diffuse optical tomography may also be applied to obtain the true optical properties within different organs, which may also improve the light propagation model. 27 In this paper, the FMT was successfully integrated onto the iSMAART research platform. The iodinated contrast CT successfully delineated the tumor volume and served as a valuable benchmark against the FMT performance. In vivo experiments performed on two breast tumor models confirmed the submillimeter accuracy of the FMT in recovery of 3D tumor location and volume information. The concept of FMT-guided radiation targeting was validated on a euthanized mouse with surgically implanted ICG-containing glass tube. The addition of FMT to the iSMAART platform has enabled online molecular imaging-guided precise focal irradiation. Of particular note, this fluorescence imaging study was conducted using a novel PLGA-anti-EGFR nanoparticle actively targeting EGFR-overexpressing breast tumors. This active targeting strategy demonstrated high efficiency in the delivery of nanoparticles to the tumor site and prolonged nanoparticle retention. This not only enables a fast imaging acquisition and prolonged imaging window, but also offers an opportunity for image-guided drug delivery when nanoparticles are conjugated with cancer targeting therapeutics. It is worth mentioning that the tumor microenvironment may change during the prolonged imaging window, resulting in a redistribution of fluorescence nanoparticles. 28 How this will impact the quantitative imaging capability requires further investigation. Nonetheless, combining accurate fluorescent imaging with active nanoparticle targeting can become a powerful tool in the study of cancer radiobiology.
In this series, the BLT and FMT have been successfully developed and integrated on the iSMAART platform, expanding its capability in performing radiobiology and radiotherapy research. Bioluminescence and fluorescence are visible or near-infrared light, and can be detected with the same CCD camera. The major difference between bioluminescence and fluorescence lies in the emitted photons. Bioluminescence is generated from the chemical reaction occurring on the tumor site, while fluorescence is generated when fluorophores are excited by incident photons of higher energy. The only difference in the system configuration is that fluorescence imaging requires an external light source, e.g., a laser, to excite the fluorophore. On the iSMAART, the BLT and FMT share the same CCD detector besides the animal stage. BLT and FMT have their own merits. Comparing with luciferases usually required in the bioluminescence imaging, fluorescent probes are more diverse and easily produced. They include dyes, proteins, quantum dots, and nanoparticles, and most of them do not need genetic manipulation of tumor cells for in vivo application. While the FMT guidance was demonstrated using active targeting fluorescence nanoparticles in this study, the same principle can be generalized to other type of fluorescence probes, such as the green fluorescence proteins, which are already heavily utilized in cancer biology. Furthermore, there are more sourcedetector pairs in the FMT acquisition, therefore FMT reconstruction is a less ill-posed mathematical problem than BLT reconstruction is. One advantage for bioluminescence imaging is its clean background, making it very specific for tumor detection, while auto-fluorescence presents a background artifact in fluorescence imaging. Nevertheless, the BLT and FMT on the iSMAART platform have shown comparable performances regarding tumor detection and radiation guidance. A comprehensive and head-to-head comparison warrants further studies.
